6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$40M | — | — | -$37M | $10M | $19M |
| 2024 | — | -$52M | — | — | -$37M | $20M | $18M |
| 2023 | — | -$35M | — | — | -$33M | — | $13M |
| 2022 | $2M | -$28M | 100.0% | -1031.4% | -$23M | — | $6M |
| 2021 | $28M | -$55M | 98.5% | -138.8% | -$53M | $0 | $89M |
| 2020 | $3M | -$80M | 58.7% | -1919.2% | -$23M | $635000 | $35M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$12M | — | — | — | $9M | $15M |
| Dec '25 | — | -$8M | — | — | -$7M | $10M | $19M |
| Sep '25 | — | -$10M | — | — | -$11M | $10M | $21M |
| Jun '25 | — | -$11M | — | — | — | $9M | $22M |
| Mar '25 | — | -$11M | — | — | — | — | $18M |
| Dec '24 | — | -$14M | — | — | -$9M | $20M | $18M |
| Sep '24 | — | -$19M | — | — | -$7M | — | $26M |
| Jun '24 | — | -$7M | — | — | -$9M | — | $3M |
| Mar '24 | — | -$12M | — | — | -$12M | — | $12M |
| Dec '23 | — | -$9M | — | — | -$10M | — | $13M |
| Sep '23 | — | -$11M | — | — | -$5M | — | $15M |
| Jun '23 | — | -$8M | — | — | -$9M | — | $22M |
| Mar '23 | $0 | -$8M | — | — | -$8M | — | $9M |
| Dec '22 | $0 | -$7M | — | — | -$7M | — | $6M |
| Sep '22 | $0 | -$7M | — | — | -$5M | — | $2M |
| Jun '22 | $653000 | -$7M | 0.0% | -954.4% | $6M | — | $598000 |
| Mar '22 | $2M | -$14M | 0.0% | -878.9% | -$16M | — | $73M |
| Dec '21 | $26M | $15M | 98.3% | 56.4% | -$14M | $0 | $89M |
| Sep '21 | $1M | -$16M | 100.0% | -1079.3% | -$15M | $0 | $103M |
| Jun '21 | $540000 | -$17M | 100.0% | -3378.5% | -$11M | $0 | $117M |
How the market has priced ELTX against its own fundamentals since 2023-06 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Elicio Therapeutics, Inc.'s revenue has declined 10.6% per year. These are computed facts, not advice.
As of FY2025, Elicio Therapeutics, Inc. reported $10M of total debt against $19M of cash; operating income covered interest expense -33.3×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.